Overview Triple Therapy in T1DM Status: Recruiting Trial end date: 2022-05-01 Target enrollment: Participant gender: Summary To assess whether the addition of dapagliflozin to semaglutide and insulin (triple therapy) improves glycemic control in patients with type 1 diabetes compared with semaglutide and insulin (dual therapy) and insulin only (standard) treatment. Phase: Phase 2/Phase 3 Details Lead Sponsor: State University of New York at BuffaloCollaborator: University of GlasgowTreatments: 2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triolDapagliflozinInsulinInsulin, Globin Zinc